Wendy Lee

发表

Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar Moiety.

Xianrui Zhao, Ignacio Aliagas, Ronen Marmorstein, 2015, ACS medicinal chemistry letters.

Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.

Xiao-Gao Liu, Barbara Hibner, Joel Renick, 2004, Bioorganic & medicinal chemistry letters.

Potent and selective aminopyrimidine-based B-Raf inhibitors with favorable physicochemical and pharmacokinetic properties.

E. Laird, Y. Ran, G. Hatzivassiliou, 2012, Journal of medicinal chemistry.

A hit to lead discovery of novel N-methylated imidazolo-, pyrrolo-, and pyrazolo-pyrimidines as potent and selective mTOR inhibitors.

S. Sideris, S. Malek, J. Lyssikatos, 2013, Bioorganic & medicinal chemistry letters.

Turning the Other Cheek: Influence of the cis-Tetrafluorocyclohexyl Motif on Physicochemical and Metabolic Properties

E. Plise, J. Crawford, Wendy Lee, 2022, ACS medicinal chemistry letters.

Synthesis of an Azabicyclo[3.1.0]hexanone-Containing Inhibitor of NF-κΒ Inducing Kinase via Catalytic C–H Activation

Matthew L Landry, J. Crawford, Wendy Lee, 2020, Synthesis.

Identification of orally available naphthyridine protein kinase D inhibitors.

I. Enyedy, T. McKinsey, Margaret R Pancost, 2010, Journal of medicinal chemistry.

Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.

Adam R. Johnson, BinQing Wei, C. Eigenbrot, 2018, Journal of medicinal chemistry.

A chemoselective Reformatsky–Negishi approach to α-haloaryl esters

J. Crawford, J. Drobnick, Wendy Lee, 2014 .

Stereochemical Differences in Fluorocyclopropyl Amides Enable Tuning of Btk Inhibition and Off-Target Activity.

Adam R. Johnson, C. Eigenbrot, J. Lubach, 2020, ACS medicinal chemistry letters.

Title Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration

J. Sivak, Fupeng Ma, P. Tarsa, 2018 .

Discovery of Oral VEGFR-2 Inhibitors with Prolonged Ocular Retention That Are Efficacious in Models of Wet Age-Related Macular Degeneration.

J. Sivak, B. Jaffee, Fupeng Ma, 2015, Journal of medicinal chemistry.

An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist.

J. Sivak, M. Mclaughlin, B. Jaffee, 2013, Journal of medicinal chemistry.

Evaluation of pharmaceutical excipients as cosolvents in 4-methyl umbelliferone glucuronidation in human liver microsomes: applications for compounds with low solubility.

U. Argikar, V. Hosagrahara, Wendy Lee, 2011, Drug Metabolism and Pharmacokinetics.

Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic Window.

I. Aliagas, K. Hoeflich, Weiru Wang, 2016, Journal of medicinal chemistry.

Discovery of 4-((2S,4S)-4-Ethoxy-1-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)piperidin-2-yl)benzoic Acid (LNP023), a Factor B Inhibitor Specifically Designed To Be Applicable to Treating a Diverse Array of Complement Mediated Diseases.

Thomas M. Smith, N. Gradoux, Jian Ding, 2020, Journal of medicinal chemistry.

Leveraging the Pre-DFG Residue Thr-406 To Obtain High Kinase Selectivity in an Aminopyrazole-Type PAK1 Inhibitor Series.

F. Diederich, G. Manning, I. Aliagas, 2015, ACS medicinal chemistry letters.

Synthesis and pharmacological characterization of a potent, orally active p38 kinase inhibitor.

S. Wilhelm, W. Scott, J. Pirro, 2002, Bioorganic & medicinal chemistry letters.

Strategies to Mitigate the Bioactivation of Aryl Amines.

Matthew L Landry, Huifen Chen, Shuguang Ma, 2020, Chemical research in toxicology.

Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat

J. Rudolph, Ning Liu, M. Durk, 2016, Drug metabolism letters.

Identification of potent and selective amidobipyridyl inhibitors of protein kinase D.

I. Enyedy, T. McKinsey, D. Lemon, 2010, Journal of medicinal chemistry.

Filling a nick in NIK: extending the half-life of a NIK inhibitor through structure-based drug design.

Matthew L Landry, P. McEwan, Adam Johnson, 2023, Bioorganic & medicinal chemistry letters.

The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.

J. Sivak, B. Jaffee, Fupeng Ma, 2018, Journal of medicinal chemistry.

Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.

I. Aliagas, K. Hoeflich, Weiru Wang, 2015, Journal of medicinal chemistry.

Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors.

A. Ebens, J. Lyssikatos, John G. Moffat, 2015, Bioorganic & medicinal chemistry letters.

Structure based design of novel 6,5 heterobicyclic mitogen-activated protein kinase kinase (MEK) inhibitors leading to the discovery of imidazo[1,5-a] pyrazine G-479.

P. Savy, Steve Price, M. Ultsch, 2014, Bioorganic & medicinal chemistry letters.

Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.

T. Chang, Thomas K. H. Chang, Jie Chen, 2001, The Journal of pharmacology and experimental therapeutics.

Structure-Guided Design of Group I Selective p21-Activated Kinase Inhibitors.

I. Aliagas, K. Hoeflich, Weiru Wang, 2015, Journal of medicinal chemistry.

Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P450 1B1.

T. Chang, Thomas K. H. Chang, Wendy Lee, 2000, Canadian journal of physiology and pharmacology.